Metformin: Maybe Not As Good As It Seems

Metformin is the most widely prescribed first-line drug for type 2 diabetes, and for good reason.

• It lowers blood sugar by reducing the liver's glucose output

• Improves insulin sensitivity

• Slows intestinal glucose absorption

• It typically drops A1c by 1 to 1.5 percent

• Rarely causes dangerously low blood sugar, and

• Is cheap and widely available.

It also has a real cardiovascular track record: in the landmark UK Prospective Diabetes Study, overweight, newly diagnosed diabetics on metformin saw heart attacks fall by 39 percent and all-cause mortality by 36 percent over roughly a decade.

That success has fueled excitement about metformin as a potential anti-aging drug, but it is worth being clear about how the drug actually works. Metformin is, in effect, a mild mitochondrial toxin. It inhibits complex I of the mitochondrial electron transport chain, which reduces the cell's ability to produce ATP. That drop in energy charge raises the AMP-to-ATP ratio, and it is this energy stress, not a direct "switch," that activates AMPK and the downstream effects (mTOR suppression, autophagy, a fasting-like state) that longevity enthusiasts find appealing.

In other words, the benefits people tout are a stress response to partially poisoned mitochondria.

Observational data hint that diabetics on metformin sometimes outlive non-diabetics, and the long-delayed TAME trial aims to test whether the drug can slow aging in people without diabetes. But that trial remains unfunded and unstarted, and current evidence doesn't support metformin for healthy people.

And when lifestyle change is put head-to-head against metformin, lifestyle tends to win.

The U.S. Diabetes Prevention Program randomized over 3,000 high-risk adults to metformin, an intensive lifestyle program, or placebo. After three years, lifestyle cut new diabetes cases by 58 percent, nearly double metformin's 31 percent. Over 21 years of follow-up, both kept an edge over placebo, but lifestyle stayed ahead throughout.

The Da Qing study in China followed participants for 30 years and produced the most striking numbers. A six-year lifestyle program of diet and exercise reduced cardiovascular events by 26 percent, cardiovascular deaths by 33 percent, and all-cause mortality by 26 percent. It increased median survival by nearly five years and raised life expectancy by about 1.4 years.

No metformin trial has yet demonstrated comparable longevity gains in people without diabetes.

There is also a serious caveat for anyone who exercises. The same complex I inhibition that drives metformin's effects appears to sabotage the body's response to training.

In a 2019 double-blind trial in older adults, metformin blunted the gains in VO2 max and insulin sensitivity from aerobic exercise and abolished the exercise-induced increase in skeletal muscle mitochondrial respiration that the placebo group enjoyed.

The drug essentially erased the mitochondrial adaptations that exercise is supposed to produce.

This matters for aging. Maintaining muscle mass and function is one of the strongest predictors of healthy aging, mobility, and survival, and exercise is the primary tool for preserving both.

If metformin interferes with the muscle and mitochondrial adaptations that training generates, then for an active person trying to age well, the drug may be working against the very thing that matters most. (It can also deplete vitamin B12 and commonly causes nausea or diarrhea.)

The takeaway is not that metformin is overrated as a diabetes therapy. It remains a safe, effective, foundational treatment, and it is genuinely useful for prediabetes, PCOS, and insulin resistance.

But for prevention and longevity in otherwise healthy, active people, the evidence points toward diet and movement as the more powerful intervention, and metformin, by partially poisoning the mitochondria and blunting exercise adaptations, may actively undercut the muscle and mitochondrial health that aging well depends on.